Biomarkers of Contrast-Induced Nephropathy After Non-cardiac Vascular Procedures: An Under-explored Area

Fabien Lareyre,Juliette Raffort

DOI: https://doi.org/10.1177/00033197211042151

2021-08-31

Angiology

Abstract:Contrast-induced nephropathy (CIN), also known as contrast-induced acute kidney injury (CI-AKI), is defined as acute renal impairment occurring 24–72 h after intravascular injection of radiographic contrast media (CM) in the absence of alternative aetiology.1–4 Its diagnosis is mainly based on the assessment of serum creatinine (sCr) levels and several definitions have been proposed depending on the time point and the cut-off value.5 sCr allows to evaluate renal function by estimating the glomerular filtration rate (eGFR) using well-established equations (eg, Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD) or Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)).6–8 While sCr is a widely used biomarker, its main limitation is a delayed increase in cases of kidney damage.9–11 It has been estimated that to have a significant measurable change in sCr, 50% of the nephrons may have already been injured.12 To cope with this limitation, several biomarkers have been proposed for their predictive ability in CI-AKI, some of them representing changes in renal function, others reflecting kidney damage.9–11 However, studies performed so far had heterogeneous designs and sometimes controversial results, making it difficult to draw clear conclusions on their use in clinical practice.

peripheral vascular disease